Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Eptifibatide clinical trials

Abciximab is a first-line GP llb/Illa receptor inhibitor for patients undergoing primary PCF " who have not received fibrinolytics. It should not be administered for medical management of the ST-segment-elevation ACS patient who will not be undergoing PCI. Abciximab is preferred over eptifibatide and tirofiban in this setting because abciximab is the most common GP Ilb/IIIa receptor inhibitor studied in primary PCI trials.Abciximab, in combination with aspirin, a thienopyridine, and UFH (administered as an infusion for the duration of the procedure), has been shown to reduce the risk of reinfarction" " " and need for repeat PCI in ST-segment-elevation ACS clinical trials. [Pg.305]

Eptifibatide has been shown to be safe and feasible for peripheral interventions (37), The INFLAME trial showed that markers of inflammation are reduced by using eptifibatide when performing peripheral interventions (38). There has been no data yet to suggest improved clinical outcomes or patency. [Pg.579]

See other pages where Eptifibatide clinical trials is mentioned: [Pg.48]    [Pg.51]    [Pg.51]    [Pg.2849]    [Pg.313]    [Pg.192]    [Pg.331]    [Pg.57]    [Pg.89]    [Pg.121]    [Pg.530]    [Pg.54]   
See also in sourсe #XX -- [ Pg.3 , Pg.3 , Pg.293 , Pg.294 ]



SEARCH



Eptifibatide

© 2024 chempedia.info